Heart Institute
São Paulo, 05403000, Brazil
NCT Number: NCT01631006
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%. Obstructive sleep apnea (OSA) is extremely common among patients with established cardiovascular disease, including hypertension and atrial fibrillation and when present may contribute to worse cardiovascular outcome. Although patients with HCM do not necessarily have typical characteristics of patients with OSA, such as obesity and increasing age, there is recent evidence that OSA is extremely common among patients with HCM, with a prevalence ranging from 32% to 71%. The presence of OSA among patients with HCM is independently associated with worse structural and functional impairment of the heart, including atrial and aorta enlargement, worse New York Heart Association functional class, and worse quality of life. Therefore, the recognition and treatment of OSA is a new area of research that may impact in the management of patients with HCM.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
São Paulo, 05403000, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A low or high CPAP pressure is delivered for 20 minutes
Time frame: acutely
University of Sao Paulo
Other
Acute Hemodynamic Effects of Continous Positive Airway Pressure (CPAP) in Patients With Hypertrophic Cardiomyopathy
Acronym: CPAPandHCM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03723655
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Scottsdale, Arizona, United States
View Trial DetailsNCT06481891
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Phoenix, Arizona, United States
View Trial DetailsNCT07023614
Aortic Stenosis, Subvalvular, Aortic Valve Disease
La Jolla, California, United States
View Trial DetailsNCT05569382
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Aarhus N, Denmark
View Trial Details